Pubblicazioni

Autori:

Capdevila, J; Tafuto, S; Krogh, M; Teulé, A; Garcia-Carbonero, R; Klümpen, H-J; Cremer, B; Sevilla, I; Eriksson, B; Tabaksblat, E; Metges, J-P; Reed, N S; Schrader, J; Navarro, V; Valentí, V; Hernando, J; Colao, A M; Vestermark, L; Carnaghi, C; Knigge, U P; Jimenez-Fonseca, P; Benavent, M; de Vos-Geelen, J; Venerito, M; Von Werder, A; Jann, H; Rinke, A; Smith, D; Hörsch, D; Starling, N; Ruszniewski, P; Baudin, E; Caroli-Bosc, F-X; Manzano, J L; Martín, M; Scarpa, A; Lawlor, R T; Ragulan, C; Ps, H; Sadanandam, A; Carmona-Bayonas, A; Salazar, R

Titolo:

Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial

Anno:

2025

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Formato:

Elettronico

Referee:

No

Nome rivista:

ESMO OPEN

ISSN Rivista:

2059-7029

N° Volume:

10

Numero o Fascicolo:

12

Intervallo pagine:

1-11

Parole chiave:

5-fluorouracil; advanced pancreatic neuroendocrine neoplasm; everolimus; panNET; sequential strategy; streptozotocin

Breve descrizione dei contenuti:

Background: Everolimus or streptozotocin plus 5-fluorouracil (STZ/5-FU) are approved treatments for patients with pancreatic neuroendocrine tumors (panNETs). The SEQTOR trial aimed to assess the optimal treatment sequence. Patients and methods: SEQTOR was an international, open-label, randomized, crossover, phase III trial that recruited adults with unresectable or metastatic, advanced, well-differentiated panNET. Patients received 10 mg/day of everolimus followed upon progression by STZ/5-FU; or the reverse sequence. The primary endpoint was the 35-month progression-free survival (PFS) rate after first- and second-line treatment; however, due to slow accrual and longer survival, it was changed to the 12-month PFS rate following first-line treatment (12-mPFS1). Results: Patients were randomized to everolimus (n = 72) or STZ/5-FU (n = 69) first. The 12-mPFS1 was 71.4% [95% confidence interval (CI) 59.4% to 81.6%] and 61.8% (95% CI 49.2% to 73.3%) (odds ratio 0.65, 95% CI 0.32-1.32) with a median PFS1 of 19.4 versus 22.7 months for everolimus and STZ/5-FU, respectively. STZ/5-FU achieved a significantly higher overall response rate in first-line (11.6% versus 30.3%, P = 0.012) and second-line (30.6% versus 9.1%, P = 0.072) treatments. No differences were shown in overall survival (median 61.7 versus 50.6 months in everolimus first and STZ/5-FU first, respectively; hazard ratio 1.43, 95% CI 0.86-2.37). Discontinuations of everolimus were more frequent. Conclusion: STZ/5-FU and everolimus were not statistically different in PFS rates, but STZ/5-FU achieved higher response rates.

Id prodotto:

148751

Handle IRIS:

11562/1177071

ultima modifica:

20 dicembre 2025

Citazione bibliografica:

Capdevila, J; Tafuto, S; Krogh, M; Teulé, A; Garcia-Carbonero, R; Klümpen, H-J; Cremer, B; Sevilla, I; Eriksson, B; Tabaksblat, E; Metges, J-P; Reed, N S; Schrader, J; Navarro, V; Valentí, V; Hernando, J; Colao, A M; Vestermark, L; Carnaghi, C; Knigge, U P; Jimenez-Fonseca, P; Benavent, M; de Vos-Geelen, J; Venerito, M; Von Werder, A; Jann, H; Rinke, A; Smith, D; Hörsch, D; Starling, N; Ruszniewski, P; Baudin, E; Caroli-Bosc, F-X; Manzano, J L; Martín, M; Scarpa, A; Lawlor, R T; Ragulan, C; Ps, H; Sadanandam, A; Carmona-Bayonas, A; Salazar, R, Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial «ESMO OPEN» , vol. 10 , n. 12 , 2025 , pp. 1-11

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo